Proactive Investors - Run By Investors For Investors

CytoDyn wins key concession from FDA for flagship HIV drug leronlimab trial

The FDA is allowing CytoDyn to increase the dose of the HIV drug leronlimab which patients in its clinical trial are receiving
scientist in a lab
Leronlimab is an injectable antibody with fewer side effects and lower toxicity than daily therapies now in use for the treatment of HIV

CytoDyn Inc (OTCMKTS:CYDY) announced Friday that it held a productive meeting with the Food and Drug Administration (FDA) in which it won key concessions for its flagship HIV drug leronlimab.

On a recent conference call with the FDA, US regulators recognized that the higher dosage of 700mg in a monotherapy trial for leronlimab, an injectable antibody which takes aim at HIV, had a much higher response rate than the 350mg dose used in a combination therapy trial.

READ: CytoDyn says it’s on the cusp of a breakthrough HIV treatment after Phase 3 trial

To avoid a delay in the filing of the drug’s Biologics License Application (BLA) submission, the FDA has agreed to accept safety data from 100 patients in the monotherapy trial with the 700mg dose of leronlimab. This concession allows for the drug’s BLA submission for the combination therapy to use 700 mg of the drug instead of the original 350 mg dose.

“The successful interim results in the 700 mg monotherapy arm prompted the FDA to allow CytoDyn to switch all remaining combination therapy patients from its CD02-Extension study from a 350 mg to a 700 mg dose,” a company statement explained.

In a statement, CytoDyn CEO Nader Pourhassan said the company is already arranging meetings with potential commercial partners to assess distribution and prepare for the drug’s anticipated approval.

 “We are extremely appreciative of the agency’s guidance for the approval process for the world’s first self-injectable antibody for HIV,” said Dr Pourhassan.

“We believe we can realize significant revenue opportunities by 2020 assuming the first approval of leronlimab,” he added.

Leronlimab is an injectable antibody that shows promise as an anti-viral agent with fewer side effects, lower toxicity and less frequent doses than daily therapies now in use for the treatment of HIV. The target of leronlimab is CCR5, a cell receptor that is the entry point for most strains of the human immunodeficiency virus (HIV), which causes acquired immune deficiency syndrome (AIDS). 

CytoDyn shares slipped 1% to finish at $0.48 on Thursday.

Contact Ellen Kelleher at [email protected]

 

View full CYDY profile View Profile

CytoDyn Timeline

Related Articles

A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
skin
Wed
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
scientist in lab
December 20 2018
Data from Midatech's MTD201 drug has validated the company's Q-Sphera sustained release technology, and other, bigger players are starting to sit up and take note
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use